Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1806 results
June 2015
-
Media ReleaseNovartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CMLPatients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
-
Media ReleaseNovartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease controlPreplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
-
Media ReleaseNovartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myelomaPanobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
-
Media ReleaseNovartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemiaArzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
-
Media ReleaseNovartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patientsNew analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
-
Media ReleaseNovartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorderPromacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low…
-
Media ReleaseNovartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and solesCosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients…
-
Media ReleaseNovartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is…
-
Media ReleaseNovartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphomaData show adult patients may achieve durable response rates, with 13 of 19 evaluable patients with relapsed/refractory non-Hodgkin lymphomas responding to therapy[1] Recent milestones for…
-
Media ReleaseNovartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needsIn Phase II studies, Zykadia (ceritinib) shrank tumors in patients with ALK+ NSCLC; comparable overall response in those with or without brain metastases[1],[2] Tafinlar (dabrafenib) and…
-
Fixing what’s lost in translation
Pagination
- ‹ Previous page
- 1
- …
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- …
- 151
- › Next page